ClinicalTrials.gg
CompletedNCT02207634EBBINGHAUSUpdated Jan 16, 2018Results posted

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

A Phase 3 interventional study of Evolocumab and Placebo in Dyslipidemia, sponsored by Amgen. Completed at 417 sites in 30 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-01-16.

Sponsored by Amgen · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,974
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing evolocumab in Dyslipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Dyslipidemias.

Enrollment
3rd of 10
1,974 · median 409
Started
2014
with 1 other
Phase 3
7 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
7 of 10
Amgen

Among the 10 studies testing evolocumab in Dyslipidemias, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 3rd registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 10 studies testing evolocumab in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing evolocumab in Dyslipidemias as a file.
02

Study summary

This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.

Read the detailed description

Participants who were enrolled in study 20110118 (FOURIER; NCT01764633) at select sites in select countries (selected based on study start-up timelines) were invited to participate in this cognitive function study, 20130385. There was no separate randomization for Study 20130385; data were analyzed according to Study 20110118 randomized treatment arm.

03

Conditions studied

  • Dyslipidemia

Keywords

  • High cholesterol
  • Treatment for high cholesterol
  • Lowering cholesterol
  • Lowering high cholesterol
  • Hypercholesterolemia
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Randomized into Study 20110118 (FOURIER; NCT01764633)

Exclusion criteria

Exclusion Criteria:

  • Current or known past diagnosis of dementia or mild cognitive impairment (MCI)
05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,974 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.

    Drug: Placebo · Drug: Background Statin Therapy

  • Experimental
    Evolocumab

    Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.

    Biological: Evolocumab · Drug: Background Statin Therapy

Interventions

  • BiologicalEvolocumab

    Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

    Also known as: AMG 145, Repatha

  • DrugPlacebo

    Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

  • DrugBackground Statin Therapy

    Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score

    Assessments were performed with the Cambridge Neuropsychological Test Automated Battery (CANTAB), a language-independent battery of computerized tests that is used to assess cognitive function. The Spatial Working Memory (SWM) test assesses the cognitive domain of executive function (high-level thinking and decision making). Patients search for colored tokens hidden inside boxes on the screen by touching them. The critical instruction is that once a token has been found inside a box, there will never be a token hidden inside that box again, so patients must not return to a box where a token has been found. The SWM strategy index of executive function represented the number of times a subject began a search with a different box. The Z score represents the standardized measure of how far an individual subject deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.

    Time frame: Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).

Secondary outcomes

  1. Mean Change From Baseline in Spatial Working Memory (SWM) Between-errors Z Score

    Assessments were performed with the CANTAB, a language-independent battery of computerized tests that is used to assess cognitive function. The Spatial Working Memory (SWM) between-errors test assesses the cognitive domain of working memory (holding material in mind while that material is being actively processed). Patients search for colored tokens hidden inside boxes on the screen by touching them. The critical instruction is that once a token has been found inside a box, there will never be a token hidden inside that box again, so patients must not return to a box where a token has been found. The SWM between-errors score is the number of times that a patient revisited a box in which a token had previously been found. The Z score represents the standardized measure of how far an individual participant deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.

    Time frame: Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).

  2. Mean Change From Baseline in Paired Associated Learning (PAL) Total Errors Adjusted Z Score

    The CANTAB PAL test assesses visuospatial episodic memory (storing/retrieving information by associating an event with a time and place). Boxes on the screen opened up one at a time to reveal a number of patterns. Participants were asked to remember the location of each pattern. After all the boxes had been opened, each pattern was then shown in the center of the screen in a randomized order, and the patient should touch the box where they think each pattern was hidden. The PAL total errors adjusted comprised the number of errors committed by a patient plus an adjustment for the estimated number of errors the patient would have made on any stages that were not reached. Z score represents the standardized measure of how far an individual patient deviates from the study cohort average at baseline. A higher Z score indicated better performance. The mean change from baseline averaged across all the visits is reported.

    Time frame: Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).

  3. Mean Change From Baseline in Reaction Time (RTI) Median 5-choice Reaction Time Z Score

    Assessments were performed with the CANTAB, a language-independent battery of computerized tests that is used to assess cognitive function. The Reaction Time (RTI) test assessed the cognitive domain of psychomotor speed (detecting and responding to a stimulus). Participants held down a button until a spot appeared in 1 of 5 circles on the screen. As soon as possible after the spot flashed up, the patient lifted their finger from the button and touched the circle in which the spot appeared. The RTI median 5-choice reaction time was the median duration between the onset of the stimulus and the release of the button. Z score represents the standardized measure of how far an individual participant deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.

    Time frame: Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).

07

Results

Posted Jan 16, 2018

Participant flow

Participants enrolled in Study 20110118 (FOURIER; NCT01764633) at select sites in select countries (based on study start-up timelines) were invited to participate in this cognitive function study. Participants were enrolled at 340 centers in 29 countries in Europe, North America, and Asia Pacific from September 2014 to July 2015.

Participant flow — Overall Study
MilestonePlaceboEvolocumab
Started990984
Received treatment990983
Completed968953
Not completed2231
Withdrew: Withdrawal by subject2131
Withdrew: Lost to follow-up10

Outcome measures

PrimaryMean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score

Assessments were performed with the Cambridge Neuropsychological Test Automated Battery (CANTAB), a language-independent battery of computerized tests that is used to assess cognitive function. The Spatial Working Memory (SWM) test assesses the cognitive domain of executive function (high-level thinking and decision making). Patients search for colored tokens hidden inside boxes on the screen by touching them. The critical instruction is that once a token has been found inside a box, there will never be a token hidden inside that box again, so patients must not return to a box where a token has been found. The SWM strategy index of executive function represented the number of times a subject began a search with a different box. The Z score represents the standardized measure of how far an individual subject deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.

Time frame:
Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).
Reported as:
Least squares mean · Z score
Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score
Z scorePlaceboEvolocumab
Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score0.1206 (0.0535 to 0.1877)0.1134 (0.0449 to 0.1820)
Statistical analysis
  • Placebo vs Evolocumab · Treatment difference: 0.0072 · 95% CI -0.0664 to 0.0808
SecondaryMean Change From Baseline in Spatial Working Memory (SWM) Between-errors Z Score

Assessments were performed with the CANTAB, a language-independent battery of computerized tests that is used to assess cognitive function. The Spatial Working Memory (SWM) between-errors test assesses the cognitive domain of working memory (holding material in mind while that material is being actively processed). Patients search for colored tokens hidden inside boxes on the screen by touching them. The critical instruction is that once a token has been found inside a box, there will never be a token hidden inside that box again, so patients must not return to a box where a token has been found. The SWM between-errors score is the number of times that a patient revisited a box in which a token had previously been found. The Z score represents the standardized measure of how far an individual participant deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.

Time frame:
Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).
Reported as:
Least squares mean · Z score
Mean Change From Baseline in Spatial Working Memory (SWM) Between-errors Z Score
Z scorePlaceboEvolocumab
Mean Change From Baseline in Spatial Working Memory (SWM) Between-errors Z Score0.1024 (0.0373 to 0.1675)0.0691 (0.0026 to 0.1355)
Statistical analysis
  • Placebo vs Evolocumab · Treatment difference: 0.0333 · 95% CI -0.0378 to 0.1045
SecondaryMean Change From Baseline in Paired Associated Learning (PAL) Total Errors Adjusted Z Score

The CANTAB PAL test assesses visuospatial episodic memory (storing/retrieving information by associating an event with a time and place). Boxes on the screen opened up one at a time to reveal a number of patterns. Participants were asked to remember the location of each pattern. After all the boxes had been opened, each pattern was then shown in the center of the screen in a randomized order, and the patient should touch the box where they think each pattern was hidden. The PAL total errors adjusted comprised the number of errors committed by a patient plus an adjustment for the estimated number of errors the patient would have made on any stages that were not reached. Z score represents the standardized measure of how far an individual patient deviates from the study cohort average at baseline. A higher Z score indicated better performance. The mean change from baseline averaged across all the visits is reported.

Time frame:
Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).
Reported as:
Least squares mean · Z score
Mean Change From Baseline in Paired Associated Learning (PAL) Total Errors Adjusted Z Score
Z scorePlaceboEvolocumab
Mean Change From Baseline in Paired Associated Learning (PAL) Total Errors Adjusted Z Score0.1098 (0.0511 to 0.1686)0.0873 (0.0273 to 0.1472)
Statistical analysis
  • Placebo vs Evolocumab · Treatment difference: 0.0226 · 95% CI -0.0422 to 0.0873
SecondaryMean Change From Baseline in Reaction Time (RTI) Median 5-choice Reaction Time Z Score

Assessments were performed with the CANTAB, a language-independent battery of computerized tests that is used to assess cognitive function. The Reaction Time (RTI) test assessed the cognitive domain of psychomotor speed (detecting and responding to a stimulus). Participants held down a button until a spot appeared in 1 of 5 circles on the screen. As soon as possible after the spot flashed up, the patient lifted their finger from the button and touched the circle in which the spot appeared. The RTI median 5-choice reaction time was the median duration between the onset of the stimulus and the release of the button. Z score represents the standardized measure of how far an individual participant deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.

Time frame:
Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).
Reported as:
Least squares mean · Z score
Mean Change From Baseline in Reaction Time (RTI) Median 5-choice Reaction Time Z Score
Z scorePlaceboEvolocumab
Mean Change From Baseline in Reaction Time (RTI) Median 5-choice Reaction Time Z Score0.0153 (-0.0529 to 0.0834)-0.0575 (-0.1270 to 0.0121)
Statistical analysis
  • Placebo vs Evolocumab · Treatment difference: 0.0727 · 95% CI -0.0022 to 0.1477

Adverse events

Collected over From the first dose of study drug to the end of study. The median duration of follow-up was 19.4 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—204/990 (20.6%)257/990 (26%)
Evolocumab—212/983 (21.6%)272/983 (27.7%)
Most frequent serious events
Showing 10 of 334
Most frequent serious events
EventPlaceboEvolocumab
Angina pectorisCardiac disorders16/99015/983
Angina unstableCardiac disorders15/99011/983
Atrial fibrillationCardiac disorders7/99013/983
Non-cardiac chest painGeneral disorders12/9906/983
PneumoniaInfections and infestations7/99010/983
Peripheral arterial occlusive diseaseVascular disorders5/99010/983
HypertensionVascular disorders5/9907/983
Carotid artery stenosisNervous system disorders5/9906/983
Peripheral ischaemiaVascular disorders4/9906/983
AnaemiaBlood and lymphatic system disorders6/9902/983
Most frequent other events
Most frequent other events
EventPlaceboEvolocumab
NasopharyngitisInfections and infestations74/990101/983
HypertensionVascular disorders66/99061/983
Upper respiratory tract infectionInfections and infestations63/99053/983
Diabetes mellitusMetabolism and nutrition disorders59/99045/983
Back painMusculoskeletal and connective tissue disorders36/99058/983

Baseline characteristics

Demographic data are provided for all enrolled participants. Baseline Cambridge Neuropsychological Test Automated Battery (CANTAB®) data are provided for all dosed participants enrolled in the study with a baseline cognitive function assessment prior to or on the first dose date of study drug and ≥ 1 post-baseline cognitive measure.

Age, Continuous
Age, Continuous(years)PlaceboEvolocumabTotal
Mean62.7 ± 8.762.9 ± 8.762.8 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEvolocumabTotal
Female274269543
Male7167151431
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEvolocumabTotal
Hispanic or Latino14923
Not Hispanic or Latino9769751951
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEvolocumabTotal
American Indian or Alaska Native213
Asian283159
Black or African American322860
Native Hawaiian or Other Pacific Islander033
White9109081818
Multiple112
Other171229
Spatial Working Memory (SWM) Strategy Index of Executive Function Raw Score
Spatial Working Memory (SWM) Strategy Index of Executive Function Raw Score(units on a scale)PlaceboEvolocumabTotal
Mean17.8 ± 3.417.8 ± 3.517.8 ± 3.4
Spatial Working Memory (SWM) Strategy Index of Executive Function Z Score
Spatial Working Memory (SWM) Strategy Index of Executive Function Z Score(Z score)PlaceboEvolocumabTotal
Mean-0.0106 ± 0.99100.0166 ± 1.00660.0026 ± 0.9983
Spatial Working Memory Between Errors Raw Score
Spatial Working Memory Between Errors Raw Score(units on a scale)PlaceboEvolocumabTotal
Mean21.0 ± 10.620.9 ± 10.221.0 ± 10.4
Spatial Working Memory Between Errors Z Score
Spatial Working Memory Between Errors Z Score(Z score)PlaceboEvolocumabTotal
Mean-0.0130 ± 1.00750.0024 ± 0.9675-0.0055 ± 0.9879

4 further baseline measures are reported on the registry.

08

Study locations

417 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Glendale, Arizona 85306, United States
  • Research Site
    Phoenix, Arizona 85018, United States
  • Research Site
    Alhambra, California 91801, United States
  • Research Site
    Banning, California 92220, United States
  • Research Site
    Harbor City, California 90710, United States
  • Research Site
    Laguna Hills, California 92653, United States
  • Research Site
    Long Beach, California 90807, United States
  • Research Site
    Long Beach, California 90822, United States
  • Research Site
    Oceanside, California 92056, United States
  • Research Site
    Oxnard, California 93030, United States
  • Research Site
    Palm Springs, California 92262, United States
  • Research Site
    Roseville, California 95661, United States
  • Research Site
    Sacramento, California 95816, United States
  • Research Site
    San Pedro, California 90732, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Aurora, Colorado 80012, United States
  • Research Site
    Colorado Springs, Colorado 80909, United States
  • Research Site
    Denver, Colorado 80218, United States
  • Research Site
    Bridgeport, Connecticut 06610, United States
  • Research Site
    Boynton Beach, Florida 33472, United States
  • Research Site
    Crystal River, Florida 34429, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    Deerfield Beach, Florida 33442, United States
  • Research Site
    Fleming Island, Florida 32003, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Palm Harbor, Florida 34684, United States
  • Research Site
    Pembroke Pines, Florida 33025, United States
  • Research Site
    Ponte Vedra, Florida 32081, United States
  • Research Site
    Saint Petersburg, Florida 33713, United States
  • Research Site
    Sarasota, Florida 34232, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Augusta, Georgia 30909, United States
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Suwanee, Georgia 30024, United States
  • Research Site
    Coeur d'Alene, Idaho 83814, United States
  • Research Site
    Addison, Illinois 60101, United States
  • Research Site
    Belleville, Illinois 62220, United States
  • Research Site
    Chicago, Illinois 60616, United States
  • Research Site
    Jerseyville, Illinois 62052, United States
  • Research Site
    Hammond, Indiana 46320, United States
  • Research Site
    Waterloo, Iowa 50702, United States
  • Research Site
    Hutchinson, Kansas 67502, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Owensboro, Kentucky 42303, United States
  • Research Site
    Baton Rouge, Louisiana 70808, United States
  • Research Site
    Hammond, Louisiana 70403, United States
  • Research Site
    Lafayette, Louisiana 70508, United States
  • Research Site
    Metairie, Louisiana 70006, United States
  • Research Site
    Monroe, Louisiana 71201, United States
  • Research Site
    Slidell, Louisiana 70458, United States
  • Research Site
    Biddeford, Maine 04005, United States
  • Research Site
    Salisbury, Maryland 21804, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Haverhill, Massachusetts 01830, United States
  • Research Site
    Newton, Massachusetts 02459, United States
  • Research Site
    Ann Arbor, Michigan 48106, United States
  • Research Site
    Grandville, Michigan 49418, United States
  • Research Site
    Lansing, Michigan 48912, United States
  • Research Site
    Muskegon, Michigan 49444, United States
  • Research Site
    Saint Paul, Minnesota 55102, United States
  • Research Site
    Jefferson City, Missouri 65109, United States
  • Research Site
    Saint Louis, Missouri 63117, United States
  • Research Site
    Saint Louis, Missouri 63128, United States
  • Research Site
    Great Falls, Montana 59405, United States
  • Research Site
    Kalispell, Montana 59901, United States
  • Research Site
    Voorhees, New Jersey 08043, United States
  • Research Site
    Westwood, New Jersey 07675, United States
  • Research Site
    Brooklyn, New York 11206, United States
  • Research Site
    Buffalo, New York 14215, United States
  • Research Site
    Cortlandt Manor, New York 10567, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New Windsor, New York 12553, United States
  • Research Site
    Rochester, New York 14609, United States
  • Research Site
    Troy, New York 12180, United States
  • Research Site
    West Seneca, New York 14224, United States
  • Research Site
    Williamsville, New York 14221, United States
  • Research Site
    Calabash, North Carolina 28467, United States
  • Research Site
    Hickory, North Carolina 28601, United States
  • Research Site
    Hickory, North Carolina 28602, United States
  • Research Site
    Mooresville, North Carolina 28117, United States
  • Research Site
    Raleigh, North Carolina 27609, United States
  • Research Site
    Tabor City, North Carolina 28463, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Grand Forks, North Dakota 58201, United States
  • Research Site
    Canton, Ohio 44708, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Columbus, Ohio 43201, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Dayton, Ohio 45414, United States
  • Research Site
    Springfield, Ohio 45505, United States

Showing the first 100 of 417 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol. 2017 Feb;40(2):59-65. doi: 10.1002/clc.22678. Epub 2017 Feb 16. PubMed 28207168 ↗
  • Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017 Aug 17;377(7):633-643. doi: 10.1056/NEJMoa1701131. PubMed 28813214 ↗
  • Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3. PubMed 33078867 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Nov 2016, 26 months.

Results were first posted in Jan 2018, 1 year 2 months after primary completion. A results delay was requested in Jun 2017.

Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 26 months is above that.

Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2014
First posted
Aug 4, 2014
StartActual
Sep 10, 2014
Primary completionActual
Nov 11, 2016
CompletionActual
Nov 11, 2016
Results delay requested
Jun 19, 2017
Results first posted
Jan 16, 2018
Last update
Jan 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02207634
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 4, 2014
Start date
Sep 10, 2014
Primary completion
Nov 11, 2016
Completion
Nov 11, 2016
Results posted
Jan 16, 2018
Last update
Jan 16, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion